# Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

> **NCT01753713** · PHASE2 · COMPLETED · sponsor: **Manmeet Ahluwalia, MD** · enrollment: 33 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** dovitinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01753713
- **Lead sponsor:** Manmeet Ahluwalia, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-20
- **Primary completion:** 2015-01-28
- **Final completion:** 2017-09-20
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753713, "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01753713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*